Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Tax Provisions (2017 - 2025)

Vanda Pharmaceuticals' Tax Provisions history spans 11 years, with the latest figure at $103.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 6611.74% year-over-year to $103.2 million; the TTM value through Dec 2025 reached $81.8 million, up 2134.99%, while the annual FY2025 figure was $81.8 million, 2134.99% up from the prior year.
  • Tax Provisions for Q4 2025 was $103.2 million at Vanda Pharmaceuticals, up from -$5.8 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $103.2 million in Q4 2025 and bottomed at -$7.9 million in Q1 2025.
  • The 5-year median for Tax Provisions is $869500.0 (2023), against an average of $4.8 million.
  • The largest YoY upside for Tax Provisions was 6611.74% in 2025 against a maximum downside of 1425.1% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $1.5 million in 2021, then soared by 83.75% to $2.7 million in 2022, then tumbled by 72.88% to $739000.0 in 2023, then tumbled by 314.48% to -$1.6 million in 2024, then surged by 6611.74% to $103.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Tax Provisions are $103.2 million (Q4 2025), -$5.8 million (Q3 2025), and -$7.7 million (Q2 2025).